Last reviewed · How we verify

Tianjin Hemay Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Tianjin Hemay Pharmaceutical Co., Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hemay022+AI Hemay022+AI phase 3 PD-L1 inhibitor PD-L1 Oncology
Lapatinib+Capecitabine Lapatinib+Capecitabine phase 3 Tyrosine kinase inhibitor + fluoropyrimidine chemotherapy HER2, EGFR (lapatinib); thymidylate synthase (capecitabine) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class
  2. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Biocad · 1 shared drug class
  5. CStone Pharmaceuticals · 1 shared drug class
  6. Celltrion · 1 shared drug class
  7. Clovis Oncology, Inc. · 1 shared drug class
  8. 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tianjin Hemay Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Tianjin Hemay Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tianjin-hemay-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related